tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
PremiumRatingsAnalyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
13d ago
Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward
Premium
Ratings
Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward
13d ago
Janux Therapeutics reports Q1 EPS (39c), consensus (52c)
Premium
The Fly
Janux Therapeutics reports Q1 EPS (39c), consensus (52c)
14d ago
Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
PremiumCompany AnnouncementsJanux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
28d ago
Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics
Premium
Ratings
Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics
29d ago
Janux Therapeutics downgraded to Underweight from Overweight at Barclays
Premium
The Fly
Janux Therapeutics downgraded to Underweight from Overweight at Barclays
1M ago
Janux announces development candidate nomination under Bristol Myers collab
PremiumThe FlyJanux announces development candidate nomination under Bristol Myers collab
2M ago
Janux Therapeutics price target lowered to $80 from $100 at Truist
Premium
The Fly
Janux Therapeutics price target lowered to $80 from $100 at Truist
3M ago
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating
Premium
Ratings
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100